fbpx

Nyheder

Lundbeckfonden Ventures nyheder

Palma, Spain and San Diego, USA, November 10, 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for vascular calcification disorders, today announces the publication of subgroup analyses from its Phase 2b CaLIPSO clinical study in Kidney International Reports. CaLIPSO studied the effect of SNF472 over 52 weeks on vascular calcification in patients receiving hemodialysis...
Acacia Pharma completes drawdown from €25 million loan facility from Cosmo Pharmaceuticals to support US launches of BARHEMSYS® and BYFAVO™ This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 9 October 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group”...
·BYFAVO expected to be commercially available in the US before the end of the year This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 6 October 2020: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a...
Sibofimloc (EB8018/TAK-018) is a first-in-class, orally administered, gut-restricted small molecule designed to reduce inflammation underlying Crohn’s disease Sibofimloc binds FimH, a novel microbiome-derived therapeutic target validated by Enterome, to selectively disarm virulent bacteria in the gut that can cause inflammation without disrupting the local microbiome Sibofimloc is advancing through clinical development under a global licensing,...
Study Being Led by Leading Ocular Oncologist, Carol L. Shields, M.D., Director, Ocular Oncology Service, Wills Eye Hospital CAMBRIDGE, Mass.–(BUSINESS WIRE)– Aura Biosciences, a clinical-stage biopharmaceutical company developing a novel class of tumor targeted therapies for initial application in primary tumors such as choroidal melanoma, today announced the dosing of the first patient in a...
EO2401 is an innovative, off-the-shelf microbiome-antigen (‘OncoMimic’) based immunotherapy candidate EO2401 combines three ‘OncoMimics’ designed to trigger the immune system into recognizing tumor cells as bacterial (i.e. non-self) and eliciting a targeted cell-killing response Clinical trial with EO2401 now underway in two cancer indications: brain cancer (glioblastoma) and adrenal tumors Paris, France and Cambridge, MA,...
Pivotal Phase 3 clinical trial of oral tebipenem HBr met primary endpoint, demonstrating statistical non-inferiority versus intravenous ertapenem in patients with complicated urinary tract infection and acute pyelonephritis Well-tolerated with comparable safety profile to intravenous ertapenem Spero intends to complete NDA submission for U.S. regulatory approval of tebipenem HBr in the second quarter of 2021 Management to host...
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 24 August 2020: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care...
– MAU868 has the potential to be the first therapeutic to prevent and treat BKVassociated diseases in transplant patients SAN DIEGO – Aug 17, 2020 – Amplyx Pharmaceuticals, a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today announced that the first patient has been dosed...
1 2 3 68

Lundbeckfonden Ventures

Nyheder

Subgroup Analyses from Sanifit’s CaLIPSO Phase 2b Clinical Study Published in Kidney International Reports
11. november 2020
Acacia Pharma Group PLC – Acacia Pharma completes drawdown from €25 million loan facility from Cosmo Pharmaceuticals to support US launches of BARHEMSYS® and BYFAVO™
9. oktober 2020
Acacia Pharma Group PLC – Acacia Pharma announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch in the US
7. oktober 2020